8 news items
Atossa Therapeutics Announces Support Of New Breast Cancer Screening Guidelines
ATOS
7 May 24
)-endoxifen, in five Phase 2 clinical trials. One of those trials, the Karisma-Endoxifen study, is investigating (Z)-endoxifen's ability to reduce mammographic
Atossa Therapeutics Announces Expanded Research Agreement With Weill Cornell Medicine To Further Evaluate Synergy Between Antibody Drug Conjugates And (Z)-Endoxifen
ATOS
29 Apr 24
have this data, we expect to move quickly into a clinical study investigating a (Z)-endoxifen / ADC combination in patients with late-line metastatic breast cancer."
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
ATOS
29 Apr 24
cancer. Once we have this data, we expect to move quickly into a clinical study investigating a (Z)-endoxifen / ADC combination in patients with late
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
ATOS
15 Apr 24
TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular analysis 2) (I-SPY 2 TRIAL) was designed to rapidly
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
ATOS
9 Apr 24
of Medicine and EVANGELINE study investigator. "The data thus far, which shows (Z)-endoxifen is beneficial and well tolerated, suggests that this treatment
gwp9ymintgeo t8qzmhytl
ATOS
1 Apr 24
: Full enrollment of Phase 2 Karisma-Endoxifen Clinical Trial – the study is investigating (Z)-endoxifen in premenopausal women
m2mhi661i84s60ocjcdm1uggk7nzc1plg2i1d7x1hjltgqd hw1zy68eb49u
ATOS
12 Mar 24
is a medical oncologist and clinical investigator at the Weill Cornell Breast Center in New York City. "We are pleased to welcome Dr
b6r2e6o8qa92 3vitfr
ATOS
22 Feb 24
and molecular-based biomarkers in addition to evaluating new investigational agents in this setting. The (Z)-endoxifen study arm is expected to enroll up
- Prev
- 1
- Next